Schrodinger, Inc.

SDGR
About the company

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery.

Country: United StatesPrice: $29.53Market Cap: $2.2B

Investment snapshot

12%positive consensus
Scored 1d ago

Positive

2

BUY / PASS

Neutral / negative

2 / 12

NEUTRAL / FAIL

Median fair value

$4.58

-84.5% vs price

Models with upside

0 / 17

Positive margin of safety

Key risk

No clean pass — all 13 investors flag at least one valuation criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #2517 (Top 81.3%)PASSFAILFAILFAILFAILFAILFAILFAILPASSNEUTRALFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/A-855.7%N/AN/AN/A-385.7%N/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-02-25

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 vs 2025-09-30 · TTM ended 2026-09-30

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-02-25

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-02-25

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-02-25

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-02-25

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-09-30

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-02-25

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-02-25

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-02-25

Score computed: 2026-11-14

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-04

Score computed: 2026-11-14

TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Where It Passes

    Where It Falls Short

    • Valuation0% pass✓ 1✗ 27▾

      No clean pass — all 13 investors flag at least one valuation criterion

      Price / 3-yr avg EPS
      ✗Graham<= 15x
      Price-to-Book Ratio6.0x
      ✗Graham<= 1.5x
      P/E x P/B
      ✗Graham<= 22.5
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      EBIT / Enterprise Value-8.4%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-8.4%, ROC=-140.2%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Price / EPS
      ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
      Price / (CFO / Shares)156.0x
      ✗Dreman< 8x
      Price / Book Value per Share6.0x
      ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
      Valuation ReasonablenessOE Yield=-4.6%
      ✗MungerP/E < 25 or Owner Earnings Yield > 5%
      P/E or FCF YieldFCF Yield=0.6%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      P/B or P/E vs. Historical AverageP/B=6.0x
      ✗MarksP/E < 15 or P/B < 2.0
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Price / FCF per Share174.1x
      ✗Ackman<= 25
      Price vs. Trailing Low260% of trailing low ($11.36)
      ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
      Net income / market capitalization-2.67%; #3649/6340 (top 57.6%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Positive book equity / market capitalization+0.1361; #4552/6449 (top 70.6%)
      ✗AsnessTop 30% of eligible cross-section
      Price / Diluted EPS
      ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
      (EPS CAGR % + Dividend Yield %) / P/E
      ✗Neff> 0.7 (Neff's published traditional edge)
      Price / Tangible Book Value per Share6.04x
      ✗SchlossP/TBV <= 1.00x (app cutoff)
      Book Value per Share Change-51.8%
      ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
      Revenue / market capitalization+0.1214; #4221/5247 (top 80.4%)
      ✗OshaughnessyTop 10% of eligible cross-section
      (Operating cash flow - capex) / market capitalization-5.27%; #2998/4519 (top 66.3%)
      ✗OshaughnessyTop 10% of eligible cross-section
      Trailing six-month price return through the evaluation date+159.72%; #193/6202 (top 3.1%)
      ✓OshaughnessyTop 10% of eligible cross-section
    • Valuation models0% pass✗ 2▾

      SDGR overvalued: all 2 models price fair value below $29.53 (median $4.58)

      Munger fair value$3.09
      ✗Munger-855.7% margin vs $29.53
      Ackman fair value$6.08
      ✗Ackman-385.7% margin vs $29.53
    • Profitability6% pass✓ 4✗ 31▾

      15 of 16 flag SDGR's profitability — Graham, Buffett, Lynch +12 more

      Positive EPS (10 years)1/8 years positive
      ✗GrahamPositive EPS every year for 10 years
      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Net Income Positive (10+ years)1/8 years positive
      ✗BuffettPositive every year for 10+ years
      ROE (up to 5-year arithmetic mean)-23.3%
      ✗Buffett> 15% arithmetic mean (app rule)
      Operating Margin (10-yr trend)-65.2% (latest)
      ✗BuffettStable or rising over 10 years
      Free Cash Flow Proxy$-98.7M
      ✗BuffettPositive and growing
      Earnings Variance (10-yr CoV)
      ✗BuffettCoV < 0.3
      Retained Earnings Effectiveness
      ✗Buffett$1 retained -> > $1 market value created
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      ROE-19.6%
      ✗Lynch> 15%
      EBIT / Enterprise Value-8.4%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-8.4%, ROC=-140.2%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Net Income / Total Assets-14.22%
      ✗PiotroskiROA > 0
      ROA Change YoY-22.73% -> -14.22% (delta: +8.51%)
      ✓PiotroskiCurrent ROA > Prior ROA
      (CFO / Total Assets) vs ROACFO/Assets=1.91%, ROA=-14.22%
      ✓PiotroskiCFO/Assets > ROA
      Gross Margin Change YoY63.6% -> 55.7%
      ✗PiotroskiImproved YoY
      Pre-Tax Income / Revenue-21.1%
      ✗Dreman>= 8%
      Net Income / Shareholders' Equity-19.6%
      ✗Dreman> 12%
      Margin of SafetyP/B=6.0x
      ✗PabraiP/B < 1.5 or P/E < 15
      Return on Equity-21.8% (3-yr avg)
      ✗AkreROE > 20% (3-year avg)
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Positive Net Income Frequency1/7 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      Operating Income / Revenue-49.6%
      ✗Ackman>= 15%
      Net Income / Shareholders Equity-19.6%
      ✗Ackman>= 15%
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Operating Margin Trend-81.9% (2023) -> -65.2% (2025)
      ✓TempletonNon-negative operating-margin trend over 3 years
      Revenue growth vs. gross and operating margin trendgross margin 64.9% -> 55.7%, operating margin -81.9% -> -65.2%
      ✓SleepRevenue rising; gross margin flat or falling; operating margin holding
      Net income / market capitalization-2.67%; #3649/6340 (top 57.6%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Gross profit / total assets+25.74%; #1670/3702 (top 45.1%)
      ✗AsnessTop 30% of eligible cross-section
      Net income / positive book equity-19.63%; #3671/5226 (top 70.2%)
      ✗AsnessTop 30% of eligible cross-section
      Negative 5-year standard deviation of ROA-0.0997; #3478/5884 (top 59.1%)
      ✗AsnessTop 30% of eligible cross-section
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
      Positive Diluted-EPS Years1/7 years positive
      ✗Schloss>= 70% positive over 5-10 observed years (app rule)
    • Debt & Leverage8% pass✓ 3✗ 12▾

      11 of 12 flag SDGR's debt & leverage — Graham, Buffett, Lynch +8 more

      LT Debt vs Net Current Assets
      ✗GrahamLT Debt <= Net Current Assets
      Debt/Equity & Interest Coverage
      ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
      Total Debt / Equity
      ✗Lynch< 0.33
      Cash - Long-term Debt
      ✗LynchPositive preferred
      LT Debt / Total Assets Change0.00% -> 0.00%
      ✓PiotroskiDecreased YoY
      Current Assets / Current Liabilities2.75
      ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
      Total Debt / Shareholders' Equity
      ✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00x
      Debt Levels
      ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
      Interest Coverage & Debt/EBITDA
      ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
      Total Debt / Shareholders Equity
      ✗Ackman<= 1.0
      Negative debt-to-equity (higher means less debt)
      ✗AsnessTop 30% of eligible cross-section
    • Cash Flow10% pass✓ 2✗ 10▾

      9 of 10 flag SDGR's cash flow — Buffett, Lynch, Dreman +6 more

      Free Cash Flow Proxy$-98.7M
      ✗BuffettPositive and growing
      FCF Positive and Growing$-116.8M
      ✗LynchPositive and growing
      Operating Cash Flow$13.9M
      ✓PiotroskiCFO > 0
      (CFO / Total Assets) vs ROACFO/Assets=1.91%, ROA=-14.22%
      ✓PiotroskiCFO/Assets > ROA
      Price / (CFO / Shares)156.0x
      ✗Dreman< 8x
      P/E or FCF YieldFCF Yield=0.6%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      FCF Positive2/7 years FCF positive
      ✗MarksPositive FCF in majority of recent years
      (OCF - CapEx) / Market Cap-5.4%
      ✗Ackman>= 4%
      Price / FCF per Share174.1x
      ✗Ackman<= 25
      Positive Operating Cash Flow frequency2/7 years positive
      ✗SleepPositive OCF in >= 70% of available years
      Operating Cash Flow - Capital Expenditures$-116.8M
      ✗Neff> $0 (app proxy for a strong fundamental case)
      (Operating cash flow - capex) / market capitalization-5.27%; #2998/4519 (top 66.3%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Growth13% pass✓ 4✗ 9▾

      7 of 8 flag SDGR's growth — Graham, Lynch, Dreman +4 more

      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      Inventory Growth vs Revenue GrowthN/A (no inventory)
      ✓LynchInventory growth < Revenue growth
      EPS Growth Direction
      ✗DremanPositive over recent years
      EPS CAGR
      ✗Dreman> 5% annualized
      Positive Net Income Frequency1/7 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      3yr Median Revenue Growth19.7%
      ✓Ackman>= 5%
      Positive EPS Growth Frequency2/5 years with positive EPS growth
      ✗AckmanPositive EPS growth in >= 3 of last 5 years
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Revenue growth vs. gross and operating margin trendgross margin 64.9% -> 55.7%, operating margin -81.9% -> -65.2%
      ✓SleepRevenue rising; gross margin flat or falling; operating margin holding
      5-year Revenue CAGR18.8%
      ✓SleepCAGR > 7%
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
    • Verdicts13% pass✓ 2✗ 13▾

      Split decision: 12 FAIL · 2 PASS · 2 NEUTRAL

      Overall verdict
      ✗GrahamFAIL (2/9)✗BuffettFAIL (0/9)✗LynchFAIL (1/7)✗GreenblattRank #2517✓PiotroskiPASS (F-Score 5)✗DremanFAIL (2/11)✗MungerFAIL (0/4)✗PabraiFAIL (0/3)✗AkreFAIL (1/6)✗MarksFAIL (0/5)✗AckmanFAIL (3/9)✗TempletonFAIL (2/8)✓SleepPASS (3/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (1/6)✗SchlossFAIL (1/7)•OshaughnessyNEUTRAL (Not ranked)
    • Efficiency25% pass✓ 3✗ 8▾

      6 of 8 flag SDGR's efficiency — Buffett, Greenblatt, Piotroski +3 more

      Current Ratio2.75
      ✓Graham>= 2.0
      ROIC (3-5 yr avg)
      ✗Buffett> 10%
      ROIC - WACC
      ✗BuffettPositive (WACC = 10%)
      EBIT / (NWC + Net Fixed Assets)-140.2%
      ✗Greenblatt> 25%
      Current Ratio Change YoY3.31 -> 2.75
      ✗PiotroskiIncreased YoY
      Revenue / Total Assets Change YoY0.25x -> 0.35x
      ✓PiotroskiImproved YoY
      Current Assets / Current Liabilities2.75
      ✓Dreman> 1.5
      Return on Invested Capital
      ✗Munger> 15%
      ROIC (high and growing)FY2023: ROIC=unavailable; FY2024: ROIC=unavailable; FY2025: ROIC=unavailable
      ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
      Reinvestment Rate x ROIC
      ✗AkreReinvestment Rate * ROIC > 10%
      ROIC (5-year)
      ✗SleepROIC > 12% in a majority of years

    Business & financials

    Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

    Company Profile

    Industry: Pharmaceutical Products
    SIC Sector: Chemicals & Pharmaceuticals
    Size: Mid Cap($2.2B)
    Revenue: $255.9M+23.3% YoY
    Net Income: $103.3M+44.8% YoY

    Financial Snapshot

    Operating Margin-65.2%
    Return on Equity-28.4%
    Debt / Equity--
    Current Ratio2.75
    EPS (Diluted)$-1.41
    Shares Retired−1.1% / −16.6% 2y

    Shareholder Return

    Fiscal 2025

    Issued 1.1% of shares last year, 16.6% issued over two.

    Buybacks
    —
    Dividends
    —

    Company Financials

    Latest TTM and quarters alongside annual years

    TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

    The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

    MetricTTM · 2026-09-30

    2025-10-01 – 2026-09-30

    Sources · derived quarter values

    Derived from cumulative filings: revenue, net income, operating income, gross profit, ebit, pre tax income, operating cash flow, depreciation amortization, capex.

    Q3 FY 2026

    2026-07-01 – 2026-09-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, depreciation amortization, capex.

    Q2 FY 2026

    2026-04-01 – 2026-06-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, depreciation amortization, capex.

    Q1 FY 2026

    2026-01-01 – 2026-03-31

    Sources
    FY 2025
    Sources
    • 10-K · 2026-02-25
    FY 2024
    Sources
    • 10-K · 2025-02-26
    FY 2023
    Sources
    • 10-K · 2024-02-28
    FY 2022
    Sources
    • 10-K · 2023-02-28
    FY 2021
    Sources
    • 10-K · 2023-02-28
    Market Cap$2.2Bcurrent------$1.0Best.$1.8Best.$1.7Best.$1.5Best.$1.8Best.
    Revenue$269.2M↑5%$64.5M↑19%$58.9M↑8%$58.6M↓2%$255.9M↑23%$207.5M↓4%$216.7M↑20%$181.0M↑31%$137.9M
    Operating Income-$133.6M↑22%-$26.1M↑43%-$41.5M↑21%-$48.8M↑4%-$166.9M↑20%-$209.3M↓18%-$177.4M↓21%-$146.8M↓32%-$111.4M
    Net Income-$59.3M↑66%-$37.7M↓15%$6.0M↑114%-$60.0M-$103.3M↑45%-$187.1M↓560%$40.7M↑127%-$149.2M↓49%-$100.4M
    EPS (Diluted)--$-0.50↓11%$0.08↑114%$-0.81↑1%$-1.41↑45%$-2.57↓576%$0.54↑126%$-2.10↓48%$-1.42
    Gross Margin58.5%↑1%59.3%↑15%55.1%↑15%50.4%↓4%55.7%↓12%63.6%↓2%64.9%↑16%55.8%↑17%47.6%
    Operating Margin-49.6%↑25%-40.5%↑52%-70.6%↑27%-83.3%↑3%-65.2%↑35%-100.8%↓23%-81.9%↓1%-81.1%-80.8%
    ROE-19.6%↑64%———-28.4%↑36%-44.4%↓698%7.4%↑122%-33.3%↓85%-18.0%
    Total Debt------------------
    Shareholders' Equity$301.8M↓6%$301.8M↓6%$329.0M↓4%$313.5M↓16%$364.1M↓14%$421.4M↓23%$548.6M↑22%$447.9M↓20%$557.1M
    Current Ratio2.75↓16%2.75↓16%2.71↓18%2.74↓21%2.75↓17%3.31↓22%4.25↓13%4.91↓28%6.85
    Debt / Equity—————————
    Operating Cash Flow-$112.6M↓9942%-$47.6M↑23%-$34.1M↑35%-$14.8M↓110%$13.9M↑109%-$157.4M↓15%-$136.7M↓14%-$119.7M↓69%-$70.7M
    Free Cash Flow-$116.8M↓3340%-$48.9M↑22%-$34.4M↑34%-$17.3M↓112%$12.5M↑108%-$164.7M↓10%-$150.1M↓18%-$127.7M↓64%-$77.8M

    Score history

    Historical Score Timeline

    Industry peers

    Industry Peers

    Similar companies in Pharmaceutical Products

    SDGR vs Peers — Financial Grading

    Revenue$255.9MBottom 25%
    Net Income$103.3MBottom 25%
    ROE-28.4%Bottom 25%
    D/E—
    Op. Margin-65.2%Bottom 25%
    Curr. Ratio2.75Median
    CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
    Merck & Co., Inc.MRK$364.3B$147.76$65.0B$18.3B34.7%0.94—1.542/95/94/70/3F-Score 41/11
    ABBOTT LABORATORIESABT$188.0B$108.52$44.3B$6.5B12.5%0.2518.2%1.583/94/92/71/3F-Score 53/11
    BRISTOL MYERS SQUIBB COBMY$129.7B$63.43$48.2B$7.1B38.2%2.4419.4%1.262/91/93/71/3F-Score 85/11
    BIO-TECHNE CorpTECH$11.4B$72.80$1.2B$73.4M3.8%—8.4%3.464/93/93/70/3F-Score 54/11
    REPLIGEN CORPRGEN$10.7B$167.79$738.3M$48.9M2.3%0.267.5%8.373/92/93/70/3F-Score 75/11
    IONIS PHARMACEUTICALS INCIONS$4.8B$29.06$943.7M$381.4M-78.0%3.60-40.4%3.833/91/91/70/3F-Score 43/11
    NEOGEN CORPNEOG$2.5B$11.23$870.4M$7.9M-0.4%0.76-2.5%3.823/91/92/70/3F-Score 64/11
    Pharvaris N.V.PHVS$2.4B$33.36—$206.4M-64.8%0.00——0/90/92/70/3F-Score 22/11